ALGS - Aligos Therapeutics to Present Multiple Posters at AASLD's The Liver Meeting® 2023 Highlighting Progress for Its Clinical Stage Portfolio including Lead THR-? Agonist for the Treatment of NASH ALG-055009; ALG-000184 the Company's Lead CAM-E Molecule
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting six posters at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14, 2023.
The posters, which include both clinical and preclinical data on the nonalcoholic steatohepatitis (NASH) program, ALG-055009, currently in Phase 2-enabling studies, as well as preclinical and clinical data from the chronic hepatitis B (CHB) portfolio, will be available on the Aligos website in the Scientific Presentations & Conferences section following the conclusion of the conference.
Poster Details (all times are ET)
Title: Safety, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidaemic subjects and relative bioavailability/food effect of a solid formulation in healthy volunteers
Poster Number: 2900-A
Abstract Number: 41459
Presenter: Stanley Wang, M.D., Ph.D.
Date and Time: Saturday, November 11, 1-2 pm
Title: Nonclinical efficacy, pharmacokinetic/pharmacodynamic (PK/PD), and toxicology profile of ALG-055009, a novel and potent thyroid hormone receptor ? agonist, for the treatment of non-alcoholic steatohepatitis (NASH)
Poster Number: 2461-C
Abstract Number: 44177
Presenter: Dinah Misner, Ph.D.
Date and Time: Saturday, November 11, 1-2 pm
Title: Preclinical resistance profile and antiviral ...